Processing your request


please wait...

 | Case Page

 | Case Page |

Case Page

 

Progenics Pharmaceuticals, Inc.

Case Summary

Progenics Pharmaceuticals, Inc. Securities Litigation

Case Summary

Case Status:    ONGOING    
On or around 11/25/2019 (Date of last review)

Filing Date: November 22, 2019

According to the Complaint, Progenics Pharmaceuticals, Inc. is an oncology company focused on the development and commercialization of targeted medicines and artificial intelligence to find, fight and follow cancer.
The Company’s pipeline includes therapeutic agents designed to precisely target cancer and prostate-specific membrane antigen targeted imaging agents for prostate cancer.

This action stems from a proposed transaction announced on October 2, 2019, pursuant to which Lantheus Holdings, Inc., parent company of Lantheus Medical Imaging, Inc., will acquire Progenics in an all-stock transaction.

On November 12, 2019, Defendants caused the Form S-4 Registration Statement (the "S-4") to be filed with the SEC in connection with the Proposed Transaction. The S-4 solicits the Company’s shareholders to vote
in favor of the Proposed Transaction. The Complaint alleges that the S-4 is materially incomplete and misleading, in violation of Sections 14(a) and 20(a) of the Exchange Act.

Company & Securities Information

Defendant: Progenics Pharmaceuticals, Inc.

COMPANY INFORMATION:

Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States

SECURITIES INFORMATION:

Ticker Symbol: PGNX
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data


"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.

First Identified Complaint

Martin Johnson, et al. v. Progenics Pharmaceuticals, Inc., et al.

COURT: D. Delaware
DOCKET #: 19-CV-02183
JUDGE: Hon. Maryellen Noreika
DATE FILED: 11/22/2019
CLASS PERIOD START: 10/02/2019
CLASS PERIOD END: 11/22/2019
PLAINTIFF FIRMS NAMED IN COMPLAINT:
  1. Faruqi & Faruqi, LLP (Wilmington 2019)
First Identified Complaint (FIC) Filings:
No Document Title Filing Date
1 Class Action Complaint for Violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 11/22/2019
2 U.S. District Court Civil Docket 11/25/2019

Reference Complaint

—Reference Complaint Complaint Related Data is not available

Related District Court Filings

—Related District Court Filings Data is not available
 
 

Cases